Article
MDM2 rs2279744 and TP53 rs1042522 polymorphisms associated with etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients.
Oncology research and treatment - 1 Jan 2014
Wang Xu, Wang Yi-Zhuo, Ma Ke-Wei, Chen Xiao, Li Wei
Abstract excerpt
BACKGROUND/AIMS: Etoposide and cisplatin (EP) chemotherapy is the most frequently used regimen in extensive-stage small-cell lung cancer (SCLC) patients, although the side effects (e.g., neutropenia) are high. This study investigates the association of the MDM2 rs2279744 and TP53 rs1042522 single-nucleotide polymorphisms (SNPs) with EP-induced grade III/IV neutropenia and with response to EP in extensive-stage...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.